

**Table S1.** Orthogonal tests factors.

Level	Factor		
	A	B	C
	Time	IRMOF-10/CUR	CUR concentration
1	6h	3:2	1mg/ml
2	12h	1:1	2mg/ml
3	24h	2:3	3mg/ml

**Table S2.** Orthogonal test results

Group	A	B	C	Drug loading/%
1	2	1	3	41.01%
2	2	3	2	61.67%
3	1	3	3	65.96%
4	3	3	1	63.29%
5	1	1	1	10.01%
6	2	2	1	43.67%
7	3	1	2	41.30%
8	3	2	3	51.94%
9	1	2	2	55.85%
K1	43.940	30.773	38.990	
K2	48.783	50.487	52.940	
K3	52.177	63.640	52.970	
R	8.237	32.867	13.980	

**Table S3.** Analysis of variance for the orthogonal test results


Source of Variance	SS	df	variance	F	P
A(Time)	102.815	2	51.408	0.427	0.701
B(IRMOF-10/CUR)	1641.843	2	820.922	6.824	0.128
C(CUR concentration)	390.044	2	195.022	1.621	0.382
Error	240.587	2	120.294		

PS:  $P < 0.05$  means the difference is significant,  $P < 0.01$  means the difference is extremely significant

Results: Taking the drug loading as the inspection index, the results of the analysis of variance showed that B (IRMOF-10/CUR) had a significant difference on the experimental results, and A (Time) and C (CUR concentration) had no significant effects. The influence of various factors on the experimental results is  $B > C > A$ . According to the intuitive analysis of the orthogonal table, the optimal drug loading conditions are:  $A_3B_3C_3$ , that is, drug loading for 24 h, IRMOF-10/CUR is 2:3, and CUR concentration is 3 mg/mL.

**Table S4.** Validation experiment results under the optimum conditions

Number	DLC (%)	Average Value (%)	RSD (%)
1	62.93	63.96	1.15
2	64.67		
3	64.16		
4	64.10		

**Figure S1:** Size distribution report of IRMOF-10.

## Size Distribution Report by Intensity

v2.2



### Sample Details

Sample Name: 1

SOP Name: mansettings.nano

General Notes:

File Name: MOF0529.dts

Dispersant Name: Methanol

Record Number: 288

Dispersant RI: 1.326

Material RI: 1.59

Viscosity (cP): 0.5476

Material Absorption: 0.010

Measurement Date and Time: 2021年6月1日 17:07:13

### System

Temperature (°C): 25.0

Duration Used (s): 70

Count Rate (kcps): 206.6

Measurement Position (mm): 3.00


Cell Description: Disposable micro cuvette (40...

Attenuator: 8


### Results

	Size (d.n...	% Intensity:	St Dev (d.n...
<b>Z-Average (d.nm):</b> 255.9	<b>Peak 1:</b> 275.8	100.0	20.14
<b>Pdl:</b> 0.243	<b>Peak 2:</b> 0.000	0.0	0.000
<b>Intercept:</b> 1.29	<b>Peak 3:</b> 0.000	0.0	0.000


Result quality **Refer to quality report**



**Figure S2:** Size distribution report of CUR@IRMOF-10.




**Figure S3:** Differential Thermogravimetric Curve (DTG) of CUR(A) and CUR@IRMOF-10(B).



**Figure S4:** High Performance Liquid Chromatography (HPLC) of CUR


Method: Using a reversed phase column, Agilent ZORBAX SB-C18 (250mm×4.6mm, 5μm). The liquid chromatography system was LC-20A high performance liquid chromatograph equipped with a DAD diode array detector. Acetonitrile-4% glacial acetic acid solution (48:52) is used as mobile phase. The flow rate was constant at 1 mL/min, the injection volume was 10 μL, and samples were maintained at 25 °C. Detection wavelength was 430 nm.




**Figure S5:** Thin Layer Chromatography (TLC) of CUR in Visible(A) and UV Light(365 nm)(B)

Method: Apply 4  $\mu\text{L}$  of CUR solution (0.5 mg/mL) on a silica gel G thin-layer plate, and use chloroform:methanol:formic acid (96:4:0.7) as the mobile phase. The thin-layer plate is placed under sunlight and ultraviolet light(365 nm). respectively.







A



B



**Figure S6:** <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of CUR



**Figure S7:**  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra of bisdemethoxycurcumin and demethoxycurcumin